OxThera, Inc.

21 articles about OxThera, Inc.

• OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function

  6/11/2021

  OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria, announces completion of its pivotal Phase 3 study and reports top line results.

• OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact® in Patients With Primary Hyperoxaluria

  4/6/2020

  OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria, announced that it has completed enrollment in its Oxabact ePHex phase III study.

• OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes

  8/23/2019

  OxThera AB announced that, based on a positive opinion from the Paediatric Committee, the EMA has agreed to the proposed PIP for Oxalobacter formigenes in the treatment of primary hyperoxaluria.

• Oxthera Presents Continuous Strong Data from an Interim Analysis of Its Phase 2 Study With Oxabact in Primary Hyperoxaluria

  6/27/2019

  OxThera AB, a privately-held biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, announced continuous strong data from a two-year interim analysis of its Phase 2 study with Oxabact® in PH.

• OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria

  6/20/2019

  OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part.

• OxThera AB is Being Granted US Patent for Oxalobacter Secretagogues

  11/15/2018

  OxThera AB today announced a granted US patent on Oxalobacter formigenes secretagogues.  

• OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD

  10/31/2018

  Efficacy and safety data from the long-term study OC5-OL-01, at the Annual Meeting of the American Society of Nephrology Kidney Week 2018 in San Diego.   

• Hugo Petit Appointed CFO of OxThera

  9/7/2018

  OxThera AB today announced the appointment of Hugo Petit as its new Chief Financial Officer. Mr Petit previously served as the Chief Financial Officer of MedCap AB.

• OxThera Updates on Phase 3 Study With Oxabact® in Primary Hyperoxaluria

  7/10/2018

  OxThera AB announced that the Phase 3 study with Oxabact(R) in Primary Hyperoxaluria (PH) is now fully open for recruitment.

• OxThera Announces the Appointment of Dr Alain Munoz to its Board of Directors

  6/12/2018

  OxThera AB announces the appointment of Dr Alain Munoz to its board of directors.  

• OxThera Announces the Randomization of the First Patient Into its Phase III EPHEX Study With Oxabact

  3/14/2018

  OxThera AB announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact.  

• OxThera Strengthens Patent Portfolio for Treatment of Hyperoxaluria

  11/9/2017

  OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families.

• Dr. Bastian Dehmel Appointed CMO Of OxThera, Inc.

  10/13/2017

• Matthew Gantz Appointed CEO Of OxThera, Inc.

  7/5/2017

• OxThera, Inc. Raises EUR 32 Million To Complete Development Of Oxabact For Treatment Of Primary Hyperoxaluria

  11/29/2016

• OxThera, Inc. Release: Oxabact® Granted European Medicines Agency Orphan Drug Designation For Treatment Of SBS

  9/23/2014

• OxThera, Inc. Receives SEK 70 Million Financing To Continue Its Key Clinical Programs

  4/16/2014

• OxThera, Inc. Coordinates FP7 Project, Elimox - €2.19 Million Provided for Drug Development in Hyperoxaluria

  9/24/2013

• OxThera, Inc. Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria

  6/4/2013

• OxThera, Inc. Resumes Clinical Development of Hyperoxaluria Therapy

  6/7/2012